Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.
Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands.
JACC Cardiovasc Interv. 2016 Mar 28;9(6):553-61. doi: 10.1016/j.jcin.2015.10.043. Epub 2016 Mar 2.
This study sought to assess sex differences in chest pain after percutaneous coronary intervention (PCI) with newer generation drug-eluting stents (DES).
Sex-based data on chest pain after PCI with DES are scarce.
The authors performed a patient-level pooled analysis of the TWENTE and DUTCH PEERS randomized trials, in which patients were treated with newer generation permanent polymer-coated DES. At 1 and 2 years, clinical follow-up was available in 99.8% and patient-reported chest pain data in 94.1% and 93.6%, respectively.
Among all 3,202 patients, the 871 (27.2%) women were older (67.5 ± 10.2 years vs. 62.8 ± 10.6 years; p < 0.001) and had more cardiovascular risk factors: diabetes (24.2% vs. 17.8%; p < 0.001), hypertension (63.6% vs. 51.6%; p < 0.001), and positive family history (54.5% vs. 50.1%; p = 0.03). At 1- and 2-year follow-up, women reported more clinically relevant chest pain (16.3% vs. 10.5%; p < 0.001, and 17.2% vs. 11.1%; p < 0.001, respectively). Multivariate analysis demonstrated that female sex independently predicted clinically relevant chest pain at 1- and 2-year follow-up both during daily activities and at minimum physical exertion/at rest (1 year adjusted odds ratio [OR]: 1.7; 95% confidence interval [CI]: 1.2 to 2.4; p = 0.002; and adjusted OR: 1.8; 95% CI: 1.3 to 2.5; p < 0.001; 2-year adjusted OR: 1.8; 95% CI: 1.3 to 2.6; p < 0.001; and adjusted OR: 1.7; 95% CI: 1.3 to 2.3; p = 0.001). Nevertheless, the 2-year rates of death, myocardial infarction, revascularization, stent thrombosis, and various composite clinical endpoints were similar for both sexes.
Although the incidence of adverse cardiovascular events was low and similar for both sexes, women showed a statistically significantly higher prevalence of clinically relevant chest pain, which might be largely related to mechanisms other than epicardial coronary obstruction.
本研究旨在评估新一代药物洗脱支架(DES)经皮冠状动脉介入治疗(PCI)后胸痛的性别差异。
关于 DES 经 PCI 后胸痛的基于性别的数据很少。
作者对 TWENTE 和 DUTCH PEERS 随机试验进行了患者水平的汇总分析,这些患者接受了新一代永久性聚合物涂层 DES 治疗。在 1 年和 2 年时,分别有 99.8%和 93.6%的患者可获得临床随访,分别有 94.1%和 93.6%的患者可获得患者报告的胸痛数据。
在所有 3202 例患者中,871 例(27.2%)女性年龄更大(67.5±10.2 岁比 62.8±10.6 岁;p<0.001),且有更多心血管危险因素:糖尿病(24.2%比 17.8%;p<0.001)、高血压(63.6%比 51.6%;p<0.001)和阳性家族史(54.5%比 50.1%;p=0.03)。在 1 年和 2 年随访时,女性报告有更多的临床相关胸痛(16.3%比 10.5%;p<0.001,17.2%比 11.1%;p<0.001)。多变量分析表明,女性在日常活动和最低体力活动/休息时的 1 年和 2 年随访中,胸痛具有临床意义,这与性别独立相关(1 年校正比值比[OR]:1.7;95%置信区间[CI]:1.2 至 2.4;p=0.002;校正 OR:1.8;95%CI:1.3 至 2.5;p<0.001;2 年校正 OR:1.8;95%CI:1.3 至 2.6;p<0.001;校正 OR:1.7;95%CI:1.3 至 2.3;p=0.001)。然而,两性的 2 年死亡率、心肌梗死、血运重建、支架血栓形成和各种复合临床终点发生率相似。
尽管两性不良心血管事件的发生率较低且相似,但女性胸痛的临床相关发生率存在统计学显著更高,这可能主要与心外膜冠状动脉阻塞以外的机制有关。